WhaleCreep

Avidity Partners Management LP 13F holdings, Q1 2023

Hedge fundSEC filingsCompare with another fundHoldings as of 2023-03-31, filed 2023-05-15

Avidity Partners Management LP disclosed 83 US equity positions worth $3.0bn in its Q1 2023 13F filing. Its largest position is ARVN at 3.9% of the reported book, followed by SGRY and BIO. Versus Q4 2022 it opened 21 new positions, added to 15, reduced 40 and exited 22.

$3.0bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
83
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
3.9%
Largest position
The largest single position as a share of the reported equity book.
32.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
47
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2022: 21 new, 15 added, 40 reduced, 22 exited

50 of 83
ARVN ARVINAS INCHealthcare3.9%$117m4.27m−14%reduced
SGRY SURGERY PARTNERS INCHealthcare3.8%$116m3.36m+7.8%added
BIO BIO RAD LABS INCHealthcare3.5%$106m221,500+140%added
ARGX ARGENX SEHealthcare3.5%$105m280,700−55%reduced
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare3.3%$99.2m677,900−6.8%reduced
REGN REGENERON PHARMACEUTICALSHealthcare3.2%$97.9m119,100–new
AKROEUR AKERO THERAPEUTICS INC–3.1%$93.6m2.45m−36%reduced
THC TENET HEALTHCARE CORPHealthcare2.9%$87.5m1.47m+105%added
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare2.8%$85.3m2.13m−29%reduced
UHS UNIVERSAL HLTH SVCS INCHealthcare2.8%$85.2m670,000−19%reduced
ACHC ACADIA HEALTHCARE COMPANY INHealthcare2.8%$84.2m1.17m0.0%held
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.7%$82.6m815,700−54%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.7%$81.6m3.87m−34%reduced
KRTX KARUNA THERAPEUTICS INC–2.4%$73.3m403,800+35%added
BDX BECTON DICKINSON & COHealthcare2.4%$71.3m288,000–new
PLRX PLIANT THERAPEUTICS INCHealthcare2.4%$70.9m2.67m+19%added
ZTS ZOETIS INCHealthcare2.3%$67.8m407,500–new
VTYXUSD VENTYX BIOSCIENCES INC–2.1%$64.2m1.92m+49%added
MRK MERCK & CO. INCHealthcare2.1%$63.8m600,000–new
SRPT SAREPTA THERAPEUTICS INCHealthcare1.9%$57.3m416,000−61%reduced
LEGN LEGEND BIOTECH CORPHealthcare1.8%$54.0m1.12m+16%added
PRTA PROTHENA CORP PLCHealthcare1.7%$51.8m1.07m−64%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare1.7%$50.4m3.67m−4.0%reduced
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare1.7%$50.4m2.93m−43%reduced
OPHTEUR IVERIC BIO INC–1.5%$45.5m1.87m+123%added
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.5%$44.2m1.74m+27%added
PACB PACIFIC BIOSCIENCES CALIF INHealthcare1.5%$44.1m3.81m–new
BSX BOSTON SCIENTIFIC CORPHealthcare1.4%$42.5m850,000−74%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare1.3%$38.2m619,200−7.6%reduced
VIR VIR BIOTECHNOLOGY INCHealthcare1.3%$38.2m1.64m+93%added
IMCR IMMUNOCORE HLDGS PLCHealthcare1.3%$38.1m769,800−33%reduced
KPTI KARYOPHARM THERAPEUTICS INCHealthcare1.2%$37.5m9.63m0.0%held
ABT ABBOTT LABORATORIESHealthcare1.2%$35.8m354,000–new
BIIB BIOGEN INCHealthcare1.2%$35.8m128,800–new
BLU BELLUS HEALTH INC NEW–1.1%$32.8m4.55m−1.0%reduced
ICLR ICON PLCHealthcare1.0%$30.5m142,900−34%reduced
BMRN BIOMARIN PHARMACEUTICAL INCHealthcare1.0%$29.2m300,575–new
RVMD REVOLUTION MEDICINES INCHealthcare1.0%$29.1m1.34m−46%reduced
ETNBGBP 89BIO INC–0.9%$28.1m1.84m–new
AMLX AMYLYX PHARMACEUTICALS INCHealthcare0.9%$26.4m900,000–new
CUREVAC N V no ticker–0.8%$24.7m3.55m–new
AVTR AVANTOR INCHealthcare0.8%$23.8m1.13m–new
NSTGEUR NANOSTRING TECHNOLOGIES INC–0.7%$21.9m2.22m+7.8%added
FUSION PHARMACEUTICALS INC no ticker–0.7%$21.5m5.70m–new
RCKT ROCKET PHARMACEUTICALS INCHealthcare0.7%$21.3m1.24m−19%reduced
KEZAR LIFE SCIENCES INC no ticker–0.7%$20.4m6.52m−3.9%reduced
BHVN BIOHAVEN LTDHealthcare0.7%$20.3m1.49m−0.3%held
COR CENCORA INCHealthcare0.7%$20.3m126,600–new
MLYS MINERALYS THERAPEUTICS INCHealthcare0.7%$19.8m1.26m–new
VERVE THERAPEUTICS INC no ticker–0.6%$19.5m1.35m−14%reduced

Exited since Q4 2022

22 rows
UTHR UNITED THERAPEUTICS CORP DEL5.1%$218m
MDGL MADRIGAL PHARMACEUTICALS INC2.9%$125m
AZN ASTRAZENECA PLC1.9%$81.4m
LLY ELI LILLY & CO1.9%$79.4m
VRTX VERTEX PHARMACEUTICALS INC1.2%$49.7m
DGX QUEST DIAGNOSTICS INC0.9%$40.4m
BNTX BIONTECH SE0.8%$32.4m
ITCIEUR INTRA-CELLULAR THERAPIES INC0.6%$26.7m
PROMETHEUS BIOSCIENCES INC no ticker0.5%$22.4m
DCPHEUR DECIPHERA PHARMACEUTICALS IN0.4%$18.5m
MEDICUS SCIENCES ACQUISITION no ticker0.1%$5.2m
GRPH GRAPHITE BIO INC0.1%$5.2m
ARYA SCIENCES ACQU CORP IV no ticker0.1%$5.0m
PANACEA ACQUISITION CORP II no ticker0.1%$5.0m
EPIEUR ESSA PHARMA INC0.1%$4.7m
HEALTH SCIENCES ACQ CORP 2 no ticker0.09%$4.0m
SOCIAL CAP SUVRETTA HLDS CRP no ticker0.05%$2.0m
SOCIAL CAP SUVRETTA HLDS CP no ticker0.05%$2.0m
SCYX SCYNEXIS INC0.04%$1.8m
FATE FATE THERAPEUTICS INC0.02%$1.1m
ZLAB ZAI LAB LTD0.02%$961k
MEDICUS SCIENCES ACQUISITION no ticker0.0%$5.2k

Sector mix

  • Healthcare82.0%
  • Unclassified18.0%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters